

1 **Original Article**

2

3 **A Multicenter, randomized, open-label, controlled trial to evaluate the efficacy and**
4 **tolerability of hydroxychloroquine and a retrospective study in adult patients with mild**
5 **to moderate Coronavirus disease 2019 (COVID-19)**

6

7 **Running title: Hydroxychloroquine for COVID-19**

8

9 **Authors**

10 Cheng-Pin Chen^{1,2*}, Yi-Chun Lin^{1,3*}, Tsung-Chia Chen⁴, Ting-Yu Tseng⁴, Hon-Lai Wong⁵,
11 Cheng-Yu Kuo⁶, Wu-Pu Lin⁷, Sz-Rung Huang⁸, Wei-Yao Wang⁹, Jia-Hung Liao¹⁰, Chung-
12 Shin Liao¹¹, Yuan-Pin Hung¹², Tse-Hung Lin¹³, Tz-Yan Chang¹³, Chin-Fu Hsiao¹⁴, Yi-Wen
13 Huang^{13,15&}, Wei-Sheng Chung^{4,16,17&}, Chien-Yu Cheng^{1,18&}, Shu-Hsing Cheng^{1,19&}, on behalf
14 of the Taiwan HCQ Study Group^

15

16 **Affiliations**

- 17 1. Department of Infectious Diseases, Taoyuan General Hospital, Ministry of Health and
18 Welfare, Taoyuan, Taiwan
- 19 2. Institute of Clinical Medicine, National Yang-Ming University, Taipei, Taiwan
- 20 3. Graduate Institute of Clinical Medicine, Taipei Medical University, Taipei, Taiwan
- 21 4. Department of Internal Medicine, Taichung Hospital, Ministry of Health and Welfare,
22 Taichung, Taiwan
- 23 5. Department of Internal Medicine, Keelung Hospital, Ministry of Health and Welfare,
24 Keelung City, Taiwan
- 25 6. Department of Internal Medicine, Pingtung Hospital, Ministry of Health and Welfare,
26 Pingtung, Taiwan
- 27 7. Department of Internal Medicine, Taipei Hospital, Ministry of Health and Welfare, New
28 Taipei City, Taiwan
- 29 8. Department of Internal Medicine, Miaoli General Hospital, Ministry of Health and
30 Welfare, Miaoli, Taiwan
- 31 9. Department of Internal Medicine, Feng Yuan Hospital, Ministry of Health and Welfare,
32 Taichung, Taiwan
- 33 10. Department of Internal Medicine, Nantou Hospital, Ministry of Health and Welfare,
34 **NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.**
Nantou, Taiwan

- 35 11. Department of Internal Medicine, Chia Yi Hospital, Ministry of Health and Welfare,
36 Chiayi, Taiwan
- 37 12. Department of Internal Medicine, Tainan Hospital, Ministry of Health and Welfare,
38 Tainan City, Taiwan
- 39 13. Department of Internal Medicine, Chang Hua Hospital, Ministry of Health and Welfare,
40 Changhua, Taiwan
- 41 14. Institute of Population Health Sciences, National Health Research Institutes, Zhunan,
42 Taiwan
- 43 15. Institute of Medicine, Chung Shan Medical University, Taichung, Taiwan
- 44 16. Department of Health Service Administration, China Medical University, Taichung,
45 Taiwan
- 46 17. Department of Healthcare Administration, Central Taiwan University of Science and
47 Technology, Taichung, Taiwan
- 48 18. School of Public Health, National Yang-Ming University, Taipei, Taiwan
- 49 19. School of Public Health, Taipei Medical University, Taipei, Taiwan

50

51 *These authors had equal contribution to the study.

52 Alternative corresponding author: Yi-Wen Huang, email: hiwen@gmail.com; Wei-Sheng
53 Chung, email: chung.w53@msa.hinet.net; Chien-Yu Cheng, email: vajien@mail.tygh.gov.tw

54 Corresponding author: Shu-Hsing Cheng, email: shcheng@mail.tygh.gov.tw

55 1492 Jhongshan Rd. Taoyuan Dist., Taoyuan City 33004, Taiwan

56 Tel: 886-3-3699721

57 Fax: 886-3-3789127

58 ^Full authorships are listed in the Acknowledgements section.

59

60

61 **Abstract**

62 **Objective**

63 In this study, we evaluated the efficacy of hydroxychloroquine (HCQ) against coronavirus
64 disease 2019 (COVID-19) via a randomized controlled trial (RCT) and a retrospective study.

65 **Methods**

66 Subjects admitted to 11 designated public hospitals in Taiwan between April 1 and May 31,
67 2020, with COVID-19 diagnosis confirmed by pharyngeal real-time RT-PCR for SARS-CoV-
68 2, were randomized at a 2:1 ratio and stratified by mild or moderate illness. HCQ 400 mg
69 twice for 1 d and HCQ 200 mg twice daily for 6 days were administered. Both study group
70 and controlled group received standard of care (SOC). Pharyngeal swabs and sputum were
71 collected every other day. The proportion and time to negative viral PCR were assessed on
72 day 14. In the retrospective study, medical records were reviewed for patients admitted before
73 March 31, 2020.

74 **Results**

75 There were 33 and 37 cases in the RCT and retrospective study, respectively. In the RCT, the
76 median times to negative rRT-PCR from randomization to hospital day 14 were 5 days (95%
77 CI; 1–9 days) and 10 days (95% CI; 2–12 days) for the HCQ and SOC groups, respectively (p
78 = 0.40). On day 14, 81.0% (17/21) and 75.0% (9/12) of the subjects in the HCQ and SOC
79 groups, respectively, had undetected virus ($p = 0.36$). In the retrospective study, 12 (42.9%) in
80 the HCQ group and 5 (55.6%) in the control group had negative rRT-PCR results on hospital
81 day 14 ($p = 0.70$).

82 **Conclusions**

83 Neither study demonstrated that HCQ shortened viral shedding in mild to moderate COVID-
84 19 subjects.

85

86 **Keywords:** COVID-19; SARS-CoV-2; rRT-PCR; randomized control trial; area under curve

87

88 Introduction

89
90 Coronavirus Disease 2019 (COVID-19) is caused by severe acute respiratory syndrome
91 coronavirus 2 (SARS-CoV-2) and is an ongoing pandemic. The outbreak was first localized to
92 Wuhan, Hubei Province, People's Republic of China (PRC) on December 31, 2019 [1]. On
93 January 30, 2020, the World Health Organization (WHO) declared that the outbreak was a
94 public health emergency of international concern and thereafter recognized it as a pandemic
95 [2,3]. As of June 20, 2020, more than eight million cases of COVID-19 have been reported in
96 187 countries and territories. More than 450,000 deaths have been associated with this
97 infection [4]. Taiwan is a close neighbor of PRC and reported its first COVID-19 case on
98 January 21, 2020 [5]. As of June 20, 2020, there were 446 confirmed COVID-19 cases in
99 Taiwan. As a result of the early implementation of social distancing, hand hygiene, and face
100 masks, Taiwan has had a low incidence of domestic COVID-19 cases [6].

101
102 There is no known effective medical treatment against COVID-19. The mechanisms of
103 potentially efficacious antiviral agents include the inhibition of RNA-dependent RNA
104 polymerase (remdesivir [7-9] and favipiravir [10]), protease inhibition (lopinavir/ritonavir [9,
105 11, 12] and ivermectin [13]), the blockade of virus-cell membrane fusion (recombinant human
106 angiotensin-converting enzyme 2 [14] and chloroquine and hydroxychloroquine (HCQ) [8,15],
107 and the modulation of the human immune system (interferon [9] and interleukin-6 blockers
108 [16,17]).

109
110 Chloroquine phosphate is a well-known antimalarial drug that has been on the market for
111 several decades. An *in vitro* study showed that chloroquine is effective against SARS-CoV-2
112 at the entry and post-entry infection stages [8]. Chloroquine may either increase endosomal
113 pH by blocking the fusion of the virus and the host cell membrane [18] or by interfering with
114 cell receptor glycosylation [19]. Chloroquine may also repress proinflammatory signaling and
115 cytokine (IL-1, IL-6, and TNF) production by inhibiting lysosome activity in antigen-
116 presenting cells [20]. Compared to chloroquine, HCQ has an additional hydroxyl group, lower
117 toxicity, and similar antiviral efficacy.

118
119 HCQ received emergency approval by the US Food and Drug Administration (FDA) for used
120 in the treatment of COVID-19 [21]. However, the efficacy of HCQ against SARS-CoV-2 has

121 been highly controversial. Certain elite journals have retracted influential papers published on
122 the efficacy of HCQ against COVID-19 [22, 23]. HCQ is widely available in Taiwan and has
123 become the potential candidate drug therapy against COVID-19 there. In addition to
124 performing a retrospective observational study, the people of Taiwan were privileged to
125 undergo a randomized clinical trial) as every confirmed COVID-19 case should be
126 quarantined and treated in hospital until viral shedding has ceased. So, an open-label RCT
127 involving multiple centers were conducted to evaluate HCQ efficacy and tolerability in adult
128 patients with mild to moderate COVID-19. Comparison would be made with the standard of
129 care treatment (SOC) in Taiwan.

130

131 **Methods**

132

133 **Clinical trial**

134

135 **Participants**

136 The clinical trial was conducted at 11 public hospitals in northern, central, and southern
137 Taiwan affiliated with the Ministry of Health and Welfare, Taiwan, between April 1 and May
138 31, 2020. Enrolled patients were aged 20–79 y and confirmed positive for SARS-CoV-2
139 infection by real-time reverse transcription polymerase chain reaction (rRT-PCR). They
140 provided signed informed consent. Upon admission, the patients were stratified into three
141 groups: (1) mild illness without evidence of infiltration according to chest roentgenography;
142 (2) moderate illness with evidence of infiltration according to chest roentgenography but
143 neither respiratory distress nor supplemental oxygen requirement; and (3) severe illness with
144 respiratory distress, oxygen supplementation, and evidence of infiltration according to chest
145 roentgenography. Participants presenting with severe illness were excluded from this study.

146 The following patients were excluded from the trial: (a) documented history of
147 hypersensitivity to quinine derivatives; (b) retinal disease; (c) hearing loss; (d) severe
148 neurological or mental illness; (e) pancreatitis; (f) lung disease; (g) liver disease (alanine
149 aminotransferase (ALT)/aspartate aminotransferase (AST) $> 3\times$ the normal upper limit); (h)
150 kidney disease (estimated glomerular filtration rate [eGFR] < 30 mL/min/1.73 m² according
151 to MDRD or CKD-EPI); (i) hematological disease; (j) cardiac conduction abnormalities at
152 electrocardiographic (ECG) screening with long QT syndrome or QTcF interval > 450 msec
153 for males and > 470 msec for females according to Fridericia's correction at screening; (k)
154 known HIV infection; (l) active hepatitis B or C without concurrent treatment (positive for
155 hepatitis B [HBsAg and HBeAg] or hepatitis C ribonucleic acid [RNA] titer $> 800,000$
156 IU/mL); (m) G6PD; (n) psychiatric disorders and alcohol/substance dependence/abuse that
157 may jeopardize patient safety; and (o) pregnant or breast-feeding women.

158

159 **Clinical course**

160 COVID-19 symptoms were recorded and followed up daily. Chest X-rays,
161 electrocardiography, and the biomarkers complete blood count, white blood cell differential
162 count, biochemistry, prothrombin time, activated partial thromboplastin time, ferritin, highly

163 active troponin I, C-reactive protein, and erythrocyte sedimentation rate were tested upon
164 admission and every 4 days after enrollment.

165

166 **PCR assay**

167 Nasopharyngeal swab and sputum were collected every other day until patient discharge
168 following three consecutive negative results or day 14 of the study, depending upon which
169 criterion was met first. SARS-CoV-2 RNA was assessed by rRT-PCR using a hydrolysis
170 probe-based system targeting genes encoding envelope (E) protein and RNA-dependent RNA
171 polymerase (R) as previously described [24]. Negative viral RNA detection was defined as
172 cycle thresholds (Ct) values > 38 for the E gene and negative for the R gene. The PCR assay
173 was conducted at the National Laboratory of the Taiwan Centers for Disease Control.

174

175 **Study design**

176 Eligible subjects were randomly assigned by an interactive web response system in a 2:1 ratio
177 to receive either HCQ plus standard of care (SOC) or SOC alone. They were stratified by mild
178 or moderate illnesses within 4 days of diagnosis. The incidence of domestic cases was low
179 and the estimated case ratio was 30:15. The HCQ administration plan was 400 mg b.i.d. on
180 day 1 and 200 mg b.i.d. for 6 days on days 2–7. Both study group and comparison group
181 received standard of care comprising supportive treatment for subjects with mild clinical
182 COVID-19 symptoms and antimicrobial therapy for subjects presenting with moderate
183 clinical COVID-19 symptoms. The treatment consisted of: (1) ceftriaxone 2 g daily for 7 days
184 ± azithromycin 500 mg on day 1 and 250 mg on days 2–5; or (2) levofloxacin 750 mg daily
185 for 5 d; or (3) levofloxacin 500 mg daily; or (4) moxifloxacin 400 mg daily for 7–14 days for
186 subjects allergic to ceftriaxone or azithromycin or according to physician discretion.
187 Oseltamivir 75 mg b.i.d. will be administered for 5 days to subjects presenting with
188 concomitant influenza A or B infection. No HCQ dose reduction, modification, or change in
189 administration frequency will be recommended during the study period. The clinical trial
190 registry number is NCT04384380.

191

192 **Outcome measurement**

193 The primary endpoint was to evaluate the efficacy of HCQ with respect to time to negative
194 rRT-PCR assessments from randomization up to 14 days. The secondary endpoints were to
195 evaluate the proportion of negative viral rRT-PCR on hospital day 14, the resolution of

196 clinical symptoms (time to clinical recovery), the proportion of discharges by day 14, and the
197 mortality rate. HCQ safety and tolerability were also evaluated.

198

199 **Statistical analysis**

200 Data were entered into an electronic clinical trial information management system (CTIMEs;
201 National Health Research Institutes, Taiwan) by study coordinators and summarized with
202 SAS[®] v. 9.2 (SAS Institute Inc., Cary, NC, USA) All treatment data will be summarized using
203 descriptive statistics including continuous variables (number of non-missing observations,
204 means, standard deviations (SD), medians, minima, and maxima), categorical variables
205 (frequencies and percentages), and time to event variables (number of non-missing
206 observations (N), medians, minima, and maxima). The negative rRT-PCR rates between
207 treatment and control arms were compared by using fisher exact test and Cochran-Mantel-
208 Haenszel (CMH) test, stratified with mild or moderate illnesses. Kaplan-Meier method was
209 used to estimate the distribution of time to negatively rRT-PCR. The median of time to
210 negatively rRT-PCR and its 95% CI were provided. The log-rank test with/without
211 adjustment by disease severity was used to compare the distribution of time to negatively
212 rRT-PCR between two arms. The Analysis of Covariance (ANCOVA) adjusted for
213 mild/moderate diseases) was performed to compare the AUC between two arms. All tests
214 were two-tailed. A P value <0.05 was considered significant.

215

216 **Ethical statement**

217 The study protocol was approved by the Institutional Review Board of Taoyuan General
218 Hospital (IRB No. TYGH109014). The study was performed according to Good Clinical
219 Practices recommended by the Declaration of Helsinki and its amendments.

220

221 **Retrospective observational study**

222 The study was conducted at aforementioned hospitals. Cases were aged 20–79 y and
223 confirmed positive for SARS-CoV-2 infection by rRT-PCR between January 25 and March
224 31, 2020. Medical registers were reviewed and clinical symptoms, laboratory data, and
225 medications were recorded. Patients who had undetected virus within 2-days of
226 hospitalization were excluded. The study protocol was approved by the Institutional Review
227 Board of Taoyuan General Hospital (IRB No. TYGH109024).

228

229 Results

230

231 Clinical trial

232 Thirty-three cases were enrolled in the RCT (Fig. 1). The mean age (SD) of the subjects was
 233 32.9 (10.7) y. Males comprised 57.6% of all subjects. A few individuals presented with
 234 underlying chronic illnesses. The initial presentation included anosmia (51.5%), cough
 235 (48.5%), ageusia (30.0%), nasal obstruction (24.2%), and sore throat (21.2%). Of these,
 236 12.1% of the cases had pneumonia according to the X-ray images (Table 1).

237

238 **Fig 1. Patient disposition in the multicenter, open-label, randomized controlled trial (a)**
 239 **and the retrospective study (b) of hydroxychloroquine.**

240 Abbreviations: HCQ: hydroxychloroquine; SOC: standard of care

241

242 **Table 1. Baseline demographic and clinical characteristics of participants in the multi-center,**
 243 **open-label, randomized clinical trial and the retrospective observational study.**

	Randomized controlled trial					
	HCQ		SOC		Overall	
No. randomized patients	21		12		33	
Mean age (Std)	33.0	(12.0)	32.8	(8.3)	32.9	(10.7)
Median (range)	30.0	(22-68)	33.5	(22-44)	31.0	(22-68)
Male (%)	11	(52.4%)	8	(66.7%)	19	(57.6%)
Stratification						
Mild (%)	19	(90.5%)	10	(83.3%)	29	(87.9%)
Moderate (%)	2	(9.5%)	2	(16.7%)	4	(12.1%)
Symptoms						
Median of QTc msec (range)	424	(356-453)	427.5	(392-458)	424	(356-458)
Anosmia (%)	11	(52.4%)	6	(50%)	17	(51.5%)
Cough (%)	9	(42.9%)	7	(63.6%)	16	(48.5%)
Ageusia (%)	4	(19.0%)	6	(50%)	10	(30.3%)
Nasal obstruction (%)	4	(19.0%)	4	(33.3%)	8	(24.2%)

Sore throat (%)	3	(14.3%)	4	(33.3%)	7	(21.2%)
Shortness of breath (%)	1	(4.8%)	1	(8.3%)	2	(6.1%)
Fever (%)	1	(4.8%)	0	(0%)	1	(3.0%)
	Retrospective observational study					
	HCQ		Control		Total	
No. patients	28		9		37	
Mean age (Std)	34.3	(14.5)	31.3	(18.0)	35.8	(14.5)
Median (range)	28	(20-66)	44	(21-56)	29	(20-66)
Male (%)	14	(50%)	3	(33.3%)	17	(45.9%)
Stratification						
Mild (%)	23	(82.1%)	6	(66.7%)	29	(78.4%)
Moderate (%)	5	(17.9%)	3	(33.3%)	8	(21.6%)
Symptoms	28		9		37	
Median of QTc msec (range)	NA		NA		NA	
Anosmia (%)	8	(28.6%)	1	(11.1%)	9	(24.3%)
Cough (%)	18	(64.3%)	3	(33.3%)	21	(56.8%)
Ageusia (%)	5	(17.9%)	1	(11.1%)	6	(16.2%)
Sore throat (%)	8	(28.6%)	2	(22.2%)	10	(27.0%)
Shortness of breath (%)	0	(0%)	1	(11.1%)	1	(2.7%)
Fever (%)	15	(53.6%)	3	(33.3%)	18	(48.6%)

244 Abbreviations: HCQ: hydroxychloroquine; SOC: standard of care; NA: not available
245

246 Twenty-one cases were randomized to the HCQ group and 12 cases were randomized to the
 247 SOC group. However, two in the HCQ group and one in the SOC group had withdrawn
 248 consents before the first dose was administered. One (4.8%) in the HCQ group and two
 249 (16.7%) in the SOC group were concomitantly administered azithromycin.
 250 The median times to negative rRT-PCR assessment from randomization to hospital day 14
 251 were 5 days (95% CI; 1–9 days) for the HCQ group and 10 days (95% CI; 2–12 days) for the
 252 SOC group ($p = 0.40$) (Fig. 2; Table 2). By day 14, 81.0% (17/21) and 75.0% (9/12) of the
 253 subjects in the HCQ and SOC groups, respectively, had undetected virus ($p = 0.36$) (Table 2).
 254 Analysis of area under curve of Ct value in the study interval showed that least square mean
 255 (SD) were 501.7 (18.0) for HCQ group and 496.6 (21.2) for SOC group. The treatment
 256 difference (95% CI) was 5.1 (-37.1 –47.2) ($p=0.81$) (Table 3). For subjects presenting with
 257 mild illness, the median times to negative rRT-PCR assessment from randomization were 5
 258 days (95% CI; 1–11 days) for the HCQ group and 11 days (95% CI; 1–12 days) for the SOC
 259 group ($p = 0.31$) (Supplemental Fig. 3; Table 4).

260

261 **Fig. 2. Probabilities of non-negative responses vs. time (days) for subjects in the HCQ**
 262 **and SOC groups in the multicenter, open-label, randomized controlled trial.**

263 **Abbreviations: HCQ: hydroxychloroquine; SOC: standard of care**

264

265 **Table 2. Proportions of negative rRT-PCR assessments on day 14 and median times to**
 266 **negative rRT-PCR results after randomization in the multicenter, open-label,**
 267 **randomized controlled trial.**

Group	N	Negative*	P-value ^{*1}	Median time to negative [#] (Days, 95% CI)	P-value ^{*2}
HCQ	21	17 (81.0%)	0.71	5 (1,9)	0.40
SOC	12	9 (75.0%)		10 (2,12)	

268 Abbreviations: HCQ: hydroxychloroquine; SOC: standard of care; CI: confidence interval;

269 *Negative event: both pharyngeal swab and sputum showed negative results; [#]Time to

270 negative = Event date or censored date – start day

271 *1 CMH test: stratified by clinical syndromes; *2 Log-rank test stratified by clinical

272 syndromes

273

274 By day 14, 28.6% of the subjects in the HCQ group and 41.7% of the subjects in the SOC
 275 group presented with clinical recovery ($p = 0.51$) (Supplemental Fig. 4; Table 5). By day 14,
 276 19.0% and 16.7% of the subjects in HCQ group and SOC group, respectively, were off-
 277 quarantined. There was no mortality in the present study.

278

279 No severe adverse events were reported in the clinical trial. Grades 1 and 2 HCQ-related
280 adverse events included headache (21.1%), dizziness (5.3%), gastritis (5.3%), diarrhea (5.3%),
281 nausea (5.3%), and photophobia (5.3%). The median QTc (ranges) were 429.5 msec (340–467)
282 on day 4 and 421 msec (391–462) on day 8. No severe prolongation was noted.

283

284 **Retrospective observational study**

285 Thirty-seven cases were enrolled in the observational study (Fig. 1). The mean age (SD) of
286 the subjects was 35.8 (14.5) y. There were 17 (45.9%) male subjects. Twenty-three (82.1%) in
287 the HCQ group and zero (0%) in the control group were administered azithromycin
288 concomitantly.

289

290 The median times (ranges) to undetected virus were 15 (6–31) days for the HCQ group and 14
291 (7–22) days for the control group ($p = 0.37$) (Supplemental Table 2.1). On hospital day 14, the
292 airway samples of 12 subjects (42.9%) in the HCQ group and 5 subjects (55.6%) in the
293 control group turned negative rRT-PCR results ($p = 0.70$). On hospital day 14, the mean log
294 change (SD) of Ct value was 7.6 (4.8) in HCQ group and 11.6 (5.6) in control group,
295 respectively ($p=0.0625$).

296

297

298 **Discussion**

299

300 The present multicenter, randomized, open-label clinical trial showed that HCQ failed the
301 primary endpoint of shortening the viral clearance interval. The retrospective study also
302 demonstrated that HCQ conferred no therapeutic benefit to the COVID-19 cases investigated
303 here.

304

305 Currently, there are > 1,000 ongoing COVID-19 clinical trials worldwide. In multicenter
306 clinical trials conducted in China, chloroquine phosphate demonstrated efficacy at preventing
307 the progression of COVID-19-related pneumonia [25]. The Chinese guideline [26]
308 recommended for adults aged 18–65 y is 500 mg twice daily for 7 days in patients weighing >
309 50 kg and 500 mg twice daily for 2 days followed by 500 mg once daily for 5 days in patients
310 weighing < 50 kg. A clinical trial in Italy was planned to include 440 patients and test two
311 different chloroquine doses but was suspended after 81 patients had been enrolled because of
312 excessive QTc prolongation and high mortality rates in the high-dose (600 mg twice daily for
313 10 days) group [27]. Compared to the study of Borba et al. [27], the participants in our
314 clinical trial were younger, did not receive high HCQ doses, and presented with a low
315 incidence of QTc prolongation.

316

317 The first open-label, non-randomized study of HCQ treatment for COVID-19 was conducted
318 in France [15]. Gautret et al. treated 20 patients with 200 mg HCQ thrice daily for 10 days.
319 Six of these patients were administered concomitant azithromycin and 16 other patients
320 received no HCQ therapy. The efficacy of HCQ at clearing the virus was remarkable: 70.0%
321 by day 6 post-inclusion in treated patients vs. 12.5% at day 6 post-inclusion in untreated
322 patients ($p < 0.001$). However, six of the patients being administered HCQ became clinically
323 worse or were lost to follow-up. Consequently, they were excluded from the final analysis and
324 interpretation of the data became very difficult. Hence, the same team performed an
325 uncontrolled non-comparative observational study on a cohort comprising 80 patients
326 presenting with mild COVID-19 symptoms who underwent HCQ and azithromycin treatment
327 [28]. Subsequently, rapid declines in nasopharyngeal viral load were reported (83% and 93%
328 of the treated patients at days 7 and 8, respectively). A large-scale observational study was
329 conducted on 1,376 COVID-19 patients in New York [29] of whom 58.9% were administered
330 HCQ 600 mg twice on day 1 and 400 mg daily thereafter for a median of 5 days. However,

331 HCQ administration was not associated with the composite intubation or death endpoint
332 (hazard ratio = 1.04; 95% CI = 0.82–1.32).

333
334 A pilot randomized controlled clinical trial (No. NCT04261517) on HCQ therapy for
335 COVID-19 was performed at a single center in Shanghai. It enrolled 30 patients with 1:1
336 randomization [30]. The study did not reveal any significant difference between the two
337 treatment groups. The viral clearance rates in the throat swab samples were relatively high by
338 day 7 after enrolment in both groups (83.7% vs. 96.3%, respectively; $p > 0.05$). Moreover, the
339 HCQ dose was comparatively low and the treatment interval was relatively short (400 mg
340 daily for 5 days; no loading). All patients in this trial received aerosolized interferon alpha
341 and most of them were also administered antiviral drugs that may have diminished or
342 augmented the therapeutic efficacy of HCQ.

343
344 Another clinical trial (No. ChiCTR2000029559) enrolled 62 subjects of whom 31 received
345 HCQ 400 mg/d for 5 days. The remaining 31 constituted the control group [31]. After 5 days,
346 the clinical recovery time of the HCQ group was significantly shortened and fever and cough
347 were alleviated relatively faster ($p < 0.05$). Pneumonia improved in 81% of the subjects in the
348 HCQ group and in 55% of the patients in the control group ($p < 0.05$). Although this study
349 corroborated the therapeutic efficacy of HCQ, it did not measure or report viral clearance
350 rates.

351
352 A recent multicenter, randomized, open-label clinical trial was conducted at 16 COVID-19
353 treatment centers in China and disclosed negative conversion rates of 85.4% and 81.3% for
354 SARS-CoV-2 28 days after randomization into HCQ + SOC and SOC groups, respectively
355 [32]. In Tang's study, 98.6% (148/150) of the enrolled subjects were categorized as
356 presenting with mild to moderate illness but 63% of the enrollees had also been treated with
357 antiviral agents (arbidol, virazole, lopinavir/ritonavir, oseltamivir, or entecavir) which may
358 have interfered with HCQ efficacy.

359
360 The strength of our RCT lies in the fact that the enrollees were randomized within 4 days of
361 diagnosis. Thus, the earliest possible intervention could be made. Clinical courses could be
362 clearly and accurately monitored because of early diagnosis and treatment with SOC or HCQ.
363 Furthermore, the HCQ treatment regimen used here consisted of loading twice with 400 mg
364 followed by 200 mg twice daily for 7 days [33]. A physiologically based pharmacokinetic

365 model indicated that the aforementioned dose used in the present study was ideal for HCQ
366 therapy [34]. Third, no antiviral therapy was given, and only 1 case in the HCQ group and 2
367 cases in the SOC group had azithromycin treatment.

368
369 In contrast, there were limitations to the present study. Only patients presenting with mild to
370 moderate disease symptoms were enrolled in order to determine the viral clearance efficacy of
371 HCQ. Hence, there is relatively little data on the impact of severe disease in terms of
372 intubation and mortality. At clinical trial launch, there were no indigenous and very few
373 imported cases in Taiwan. Therefore, study enrollment was prematurely stopped. The low
374 case numbers in the present study might account for the apparent lack of superior efficacy of
375 HCQ. However, 81% of the HCQ group and 75% of the SOC group had confirmed viral
376 clearance on hospital day 14. Moreover, according to Taiwan CDC regulations, subjects could
377 not be off-quarantine until they presented with at least three consecutive negative rRT-PCR
378 results. The outcome of this RCT may assist the Taiwan CDC in their decision to release
379 quarantined patients when medical resources are in short supply. Another limitation of the
380 study was that the mean patient age (SD) was 32.9 (10.7) y as opposed to 51.1 y (13.9) for
381 Borba et al., 45.1 y for Gautret et al., 44.7 y (15.3) for Chen et al., and 46.1 y (14.7) for Tang
382 et al. [15,27,31,32]. For this reason, the observed rates of cardiac and retinal toxicity were low
383 in the present study. Electrocardiogram monitoring was performed frequently and close
384 attention was paid to any changes in patient QTc interval, vision, and neurological symptoms.
385 Lastly, readers might question about the gap in median time to negative viral detection
386 between retrospective observational study and RCT. Since the date of HCQ initiation was
387 very diverse, and the frequency of viral sampling was not the same in the retrospective
388 observational cohort, the different outcome comparing to RCT was not surprised.

389

390 **Conclusions**

391

392 Both the retrospective and randomized clinical studies performed here failed to demonstrate
393 HCQ efficacy at shortening viral shedding in subjects presenting with mild to moderate
394 COVID-19 symptoms. Future research should conduct large-scale studies involving more
395 patients to investigate new agents or combinational therapy, and explore the viral dynamics.

396

397 **Acknowledgements**

398

399 The authors thank the Hospital and Social Welfare Organizations Administration Commission,
400 Ministry of Health and Welfare for their research grant. This funding source played no role in
401 study design or conduction, data collection, analysis or interpretation, writing of the
402 manuscript, or decision to submit it for publication. The authors also thank Taiwan Biotech
403 Co. Ltd. for their donation of investigational products, the National Health Research Institutes,
404 Taiwan Centers for Disease Control, Taiwan Food and Drug Administration, Center for Drug
405 Evaluation, Taiwan for their technical assistance, and all study members participating in the
406 Taiwan HCQ Study Group led by Shu-Hsing Cheng (shcheng@mail.tygh.gov.tw), namely,
407 Chien-Yu Cheng*, Yi-Chun Lin*, Cheng-Pin Chen*, and Shu-Hsing Cheng* from Taoyuan
408 General Hospital, Ministry of Health and Welfare, Chin-Feng Lin, Jiing-Chyuan Luo, Fu-
409 Shun Tsai, Tsung-Yen Yang, Wen-Chen Yau, and Hon-Lai Wong* from Keelung Hospital,
410 Ministry of Health and Welfare, Wu-Pu Lin*, Lin-Chen Chien, Chen-Han Yiu, Chien-Yu
411 Huang, and Yung-Tsung Hsiao from Taipei Hospital, Ministry of Health and Welfare, Ming-
412 Huei Lee and Sz-Rung Huang* from Miaoli General Hospital, Ministry of Health and
413 Welfare, Wei-Sheng Chung*, Tsung-Chia Chen*, and Ting-Yu Tseng* from Taichung
414 Hospital, Ministry of Health and Welfare, Wei-Yao Wang*, Yih-Fang Liou, and Chen-Feng
415 Chiu from Feng Yuan Hospital, Ministry of Health and Welfare, Yi-Wen Huang*, Yang-Hao
416 Yu, Tse-Hung Lin*, and Tz-Yan Chang* from Chang Hua Hospital, Ministry of Health and
417 Welfare, Hung-Chang Hung, Tzung-Fan Chuang, Jia-Hung Liao*, Li-Yueh Yeh, and Shu-
418 Ming Huang from Nantou Hospital, Ministry of Health and Welfare, Yuan-Der Huang, Shih-
419 Tien Chen, Chi-Min Shin, and Chung-Shin Liao* from Chia Yi Hospital, Ministry of Health
420 and Welfare, Yuan-Pin Hung*, Chih-I Lee, and Chun-Wei Chiu from Tainan Hospital,
421 Ministry of Health and Welfare, and Shah-Hwa Chou, Cheng-Yu Kuo*, Tz-Lun Hung, and
422 Hsin-Hui Wang from Pingtung Hospital, Ministry of Health and Welfare, and Chin-Fu Hsiao
423 from Institute of Population Health Sciences, National Health Research Institutes, Zhunan,
424 Taiwan. *Authorships.

425

426 **Conflict of interest:** none

427

428

429 **References**

430

- 431 1. World Health Organization. Naming the coronavirus disease (COVID-19) and the viral
432 that caused it, [https://www.who.int/emergencies/diseases/novel-coronavirus-2019/technical-](https://www.who.int/emergencies/diseases/novel-coronavirus-2019/technical-guidance/naming-the-coronavirus-disease-(covid-2019)-and-the-virus-that-causes-it)
433 [guidance/naming-the-coronavirus-disease-\(covid-2019\)-and-the-virus-that-causes-it](https://www.who.int/emergencies/diseases/novel-coronavirus-2019/technical-guidance/naming-the-coronavirus-disease-(covid-2019)-and-the-virus-that-causes-it) [accessed 20
434 June 2020].
- 435 2. World Health Organization. Statement on the second meeting of the International Health
436 Regulations (2005) Emergency Committee regarding the outbreak of novel coronavirus
437 (2019-nCoV), [https://www.who.int/news-room/detail/30-01-2020-statement-on-the-second-](https://www.who.int/news-room/detail/30-01-2020-statement-on-the-second-meeting-of-the-international-health-regulations-(2005)-emergency-committee-regarding-the-outbreak-of-novel-coronavirus-(2019-ncov))
438 [meeting-of-the-international-health-regulations-\(2005\)-emergency-committee-regarding-the-](https://www.who.int/news-room/detail/30-01-2020-statement-on-the-second-meeting-of-the-international-health-regulations-(2005)-emergency-committee-regarding-the-outbreak-of-novel-coronavirus-(2019-ncov))
439 [outbreak-of-novel-coronavirus-\(2019-ncov\)](https://www.who.int/news-room/detail/30-01-2020-statement-on-the-second-meeting-of-the-international-health-regulations-(2005)-emergency-committee-regarding-the-outbreak-of-novel-coronavirus-(2019-ncov)) [accessed 20 June 2020].
- 440 3. World Health Organization. WHO director-general’s opening remarks at the media
441 briefing on COVID-19, [https://www.who.int/dg/speeches/detail/who-director-general-s-](https://www.who.int/dg/speeches/detail/who-director-general-s-opening-remarks-at-the-media-briefing-on-covid-19---11-march-2020)
442 [opening-remarks-at-the-media-briefing-on-covid-19---11-march-2020](https://www.who.int/dg/speeches/detail/who-director-general-s-opening-remarks-at-the-media-briefing-on-covid-19---11-march-2020) [accessed 20 June 2020].
- 443 4. World Health Organization. Novel coronavirus situation report-151. Geneva, Switzerland,
444 [https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200619-covid-19-](https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200619-covid-19-sitrep-151.pdf?sfvrsn=8b23b56e_2)
445 [sitrep-151.pdf?sfvrsn=8b23b56e_2](https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200619-covid-19-sitrep-151.pdf?sfvrsn=8b23b56e_2) [accessed 20 June 2020].
- 446 5. Cheng SC, Chang YC, Fan Chiang YL, Chien YC, Cheng M, Yang CH et al. First case of
447 coronavirus disease 2019 (COVID-19) pneumonia in Taiwan. *J Formos Med Assoc.*
448 *2020;119(3):747–51. pii: S0929-6646(20)30044-9.*
449 <https://doi.org/10.1016/j.jfma.2020.02.007>. [Epub ahead of print].
- 450 6. Taiwan Centers for Disease Control. CECC confirmed 1 more imported COVID-19
451 case;case returns to Taiwan from Bangladesh.
452 <https://www.cdc.gov.tw/En/Bulletin/Detail/I7L0KFRR2KRBn1JygBFPUg?typeid=158>[ac
453 cessed 20 June 2020].
- 454 7. Holshue ML, DeBolt C, Lindquist S, Lofy KH, Wiesman J, Bruce H et al. First case of
455 2019 novel coronavirus in the United States. *N Engl J Med.* *2020;382(10):926–32.*
456 <https://doi.org/10.1056/NEJMoa2001191>. [Epub ahead of print].
- 457 8. Wang M, Cao R, Zhang L, Yang X, Liu J, Xu M et al. Remdesivir and chloroquine
458 effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. *Cell Res*
459 *2020;30(3):269–71. https://doi.org/10.1038/s41422-020-0282-0.* [Epub ahead of print].
- 460 9. Sheahan TP, Sims AC, Leist SR, Schäfer A, Won J, Brown AJ et al. Comparative
461 therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon

- 462 beta against MERS-CoV. *Nat Commun* 2020;11(1):222. [https://doi.org/10.1038/s41467-](https://doi.org/10.1038/s41467-019-13940-6)
463 019-13940-6.
- 464 10. Furuta Y, Komeno T, Nakamura T. Favipiravir (T-705), a broad spectrum inhibitor of
465 viral RNA polymerase. *Proc Jpn Acad Ser B Phys Biol Sci* 2017;93(7):449–63.
466 <https://doi.org/10.2183/pjab.93.027>.
- 467 11. Cheng CY, Li YL, Chen CP, Lin YC, Liu CE, Liao CH et al. Lopinavir/ritonavir did not
468 shorten the duration of SARS CoV-2 shedding in patients with mild pneumonia in Taiwan.
469 *J Microbiol Infect Immunol* 2020;53(3):488-92 [Web/URL [PM:32331982](https://pubmed.ncbi.nlm.nih.gov/32331982/)].
470 <https://doi.org/10.1016/j.jmii.2020.03.032>.
- 471 12. Cao B, Wang Y, Wen W, Liu W, Wang J, Fan G et al. A trial of lopinavir-ritonavir in
472 adults hospitalized with severe COVID-19. *New Engl J Med* 2020;382(19):1787–99.
473 Web/URL: [PM:32187464](https://pubmed.ncbi.nlm.nih.gov/32187464/). <https://doi.org/10.1056/NEJMoa2001282>.
- 474 13. Caly L, Druce JD, Catton MG, Jans DA, Wagsta KM. The FDA-approved drug
475 ivermectin inhibits the replication of SARS-CoV-2 in vitro. *Antiviral Res*
476 2020;178:104787. <https://doi.org/10.1016/j.antiviral.2020.104787>.
- 477 14. Monteil V, Kwon H, Prado P, Hagelkruys A, Wimmer RA, Stahl M et al. Inhibition of
478 SARS-CoV-2 infections in engineered human tissues using clinical-grade soluble human
479 ACE2. *Cell* 2020;181(4):905–13. Web/URL: [PM:32333836](https://pubmed.ncbi.nlm.nih.gov/32333836/).
480 <https://doi.org/10.1016/j.cell.2020.04.004>.
- 481 15. Gautret P, Lagier JC, Parola P, Hoang VT, Meddeb L, Mailhe M et al.
482 Hydroxychloroquine and azithromycin as a treatment of COVID-19: Results of an open-
483 label non-randomized clinical trial. *Int J Antimicrob Agents*. 2020;20:105949.
484 <https://doi.org/10.1016/j.ijantimicag.2020.105949>. [Epub ahead of print].
- 485 16. Giamarellos-Bourboulis EJ, Netea MG, Rovina N, Akinosoglou K, Antoniadou A,
486 Antonakos N et al. Complex immune dysregulation in COVID-19 patients with severe
487 respiratory failure. *Cell Host Microbe* 2020;27(6):992–1000. Web/URL: [PM:32320677](https://pubmed.ncbi.nlm.nih.gov/32320677/).
488 <https://doi.org/10.1016/j.chom.2020.04.009>.
- 489 17. Rose-John S. IL-6 trans-signaling via the soluble IL-6 receptor: Importance for the pro-
490 inflammatory activities of IL-6. *Int J Biol Sci* 2012;8(9):1237–47.
491 <https://doi.org/10.7150/ijbs.4989>.
- 492 18. Savarino A, Boelaert JR, Cassone A, Majori G, Cauda RE. Effects of chloroquine on viral
493 infections: An old drug against today's diseases. *Lancet Infect Dis* 2003;3(11):722–27.
494 [https://doi.org/10.1016/s1473-3099\(03\)00806-5](https://doi.org/10.1016/s1473-3099(03)00806-5).
- 495 19. Vincent MJ, Bergeron É, Benjannet S, Erickson BR, Rollin P, Ksiazek TG et al.

- 496 Chloroquine is a potent inhibitor of SARS coronavirus infection and spread. *Virology* 2005;269. <https://doi.org/10.1016/j.virol.2005.05.010>.
- 497
- 498 20. Zhang Y, Xu Q, Sun Z, Zhou L. Current targeted therapeutics against COVID-19: Based
499 on first-line experience in China. *Pharmacol Res* 2020;157:104854.
500 <https://doi.org/10.1016/j.phrs.2020.104854>.
- 501 21. U.S. Food and Drug Administration. Reply to request for emergency use authorization for
502 use of chloroquine phosphate or hydroxychloroquine sulfate supplied from the strategic
503 national stockpile for treatment of 2019 Coronavirus Disease,
504 <https://www.fda.gov/media/136534/download> [accessed 20 June 2020].
- 505 22. Mehra MR, Desai SS, Kuy S, Henry TD, Patel AN. Retraction: Cardiovascular disease,
506 drug therapy, and mortality in Covid-19. *N Engl J Med* 2020;NEJMc2021225.
507 <https://doi.org/10.1056/NEJMoa2007621>.
- 508 23. Mehra MR, Ruschitzka F, Patel AN. Retraction—hydroxychloroquine or chloroquine with
509 or without a macrolide for treatment of COVID-19: A multinational registry analysis.
510 *Lancet* 2020;395(10240):1820. [https://doi.org/10.1016/S0140-6736\(20\)31324-6](https://doi.org/10.1016/S0140-6736(20)31324-6).
- 511 24. World Health Organization. Diagnostic detection of 2019-nCoV by real-time RT-PCR,
512 [https://www.who.int/docs/default-source/coronaviruse/protocol-v2-](https://www.who.int/docs/default-source/coronaviruse/protocol-v2-1.pdf?sfvrsn=a9ef618c_2)
513 [1.pdf?sfvrsn=a9ef618c_2](https://www.who.int/docs/default-source/coronaviruse/protocol-v2-1.pdf?sfvrsn=a9ef618c_2) [accessed 20 June 2020].
- 514 25. Gao J, Tian Z, Yang X. Breakthrough: Chloroquine phosphate has shown apparent
515 efficacy in treatment of COVID-19 associated pneumonia in clinical studies. *Biosci*
516 *Trends* 2020;14(1):72–3. <https://doi.org/10.5582/bst.2020.01047>.
- 517 26. National Health Commission of the People’s Republic of China. National
518 recommendations for diagnosis and treatment of respiratory infections caused by 2019-
519 nCoV (6th ed),
520 <http://www.nhc.gov.cn/yzygj/s7653p/202002/8334a8326dd94d329df351d7da8aefc2/files/b218cfeb1bc54639af227f922bf6b817.pdf>. [accessed 6 June 2020].
- 521
- 522 27. Borba MGS, Val FFA, Sampaio VS, Alexandre MAA, Melo GC, Brito M et al. Effect of
523 high vs low doses of chloroquine diphosphate as adjunctive therapy for patients
524 hospitalized with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
525 infection: A randomized clinical trial. *JAMA Netw Open* 2020;3(4):e208857.
526 <https://doi.org/10.1001/jamanetworkopen.2020.8857>.
- 527 28. Gautret P, Lagier JC, Parola P, Hoang VT, Meddeb L, Sevestre J et al. Clinical and
528 microbiological effect of a combination of hydroxychloroquine and azithromycin in 80
529 COVID-19 patients with at least a six-day follow up: An observational study. *Travel Med*

- 530 Infect Dis 2020;34:101663. <https://doi.org/10.1016/j.tmaid.2020.101663>.
- 531 29. Geleris J, Sun Y, Platt J, Zucker J, Baldwin M, Hripcsak G et al. Observational study of
532 hydroxychloroquine in hospitalized patients with Covid-19. *New Engl J Med* 2020;
533 7:NEJMoa2012410. <https://doi.org/10.1056/NEJMoa2012410>.
- 534 30. Chen J, Liu D, Liu L, Liu P, Xu Q, Xia L et al. A pilot study of hydroxychloroquine in
535 treatment of patients with common coronavirus disease-19 (COVID-19). *Zhejiang Da Xue*
536 *Xue Bao Yi Xue Ban* 2020;49(2):215–19. [in Chinese].
- 537 31. Chen Z, Hu J, Zhang Z, Jiang S, Han S, Yan S et al. Efficacy of hydroxychloroquine in
538 patients with COVID-19: Results of a randomized clinical trial.
539 <https://doi.org/10.1101/2020.03.22.20040758>. [ahead of print].
- 540 32. Tang W, Cao Z, Han M, Wang Z, Chen J, Sun W et al. Hydroxychloroquine in patients
541 with mainly mild to moderate coronavirus disease 2019: Open label, randomized
542 controlled trial. *BMJ* 2020;369:m1849. <https://doi.org/10.1136/bmj.m1849>.
- 543 33. Taiwan CDC. Interim guidelines for clinical management of SARS-CoV-2 infection (5th
544 ed.), https://www.cdc.gov.tw/File/Get/-ewtg9-RCAetCPKR4_rmCw [accessed 6 June 2020].
- 545 34. Yao X, Ye F, Zhang M, Cui C, Huang B, Niu P et al. In vitro antiviral activity and
546 projection of optimized dosing design of hydroxychloroquine for the treatment of severe
547 acute respiratory syndrome coronavirus 2(SARS-CoV-2). *Clin Infect Dis* 2020;ciaa237.
548 <https://doi.org/10.1093/cid/ciaa237>.





